Johnson & Johnson surpasses revenue expectations in Q1 due to growth in innovative medicine and MedTech

From StockStory.org is an independent media company.: 2025-04-22 22:54:00

Johnson & Johnson (JNJ) exceeded revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint was 1.8% above analysts’ estimates. Non-GAAP profit of $2.77 per share was 7.3% above consensus. CEO highlighted growth in innovative medicine and MedTech segments, despite biosimilar competition for STELARA. Management sees 2025 as a catalyst year, focusing on expanding key brands and executing acquisitions. Analysts questioned margin drivers and biosimilar erosion. StockStory team will monitor new indications, MedTech margin improvement, and regulatory progress.

Market indices hit historic highs post-Trump’s victory, but 2025 outlook is uncertain due to new trade policies. StockStory offers a list of top growth stocks for high-quality investors, with market-beating returns. Explore opportunities for growth regardless of the macroeconomic climate. Discover potential winners like Nvidia and Comfort Systems that have shown significant returns over the past five years.



Read more at StockStory.org is an independent media company.: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations